arrow_back Back to App

Request for Information on COVID-19 Vaccine IP Waiver

This document is a request to the U.S. President to provide information to the House of Representatives regarding a proposed waiver of intellectual property rights for COVID-19 vaccines. The aim is to assess whether such a waiver would truly increase vaccine supply and accelerate the pandemic's end, and if China would gain access to these technologies.
Key points
The House wants to know if waiving intellectual property rights for COVID-19 vaccines will increase global supply and delivery.
The request also seeks to determine if such a waiver will accelerate the end of the COVID-19 pandemic.
There is concern about whether China would gain access to vaccine patents, even if explicitly excluded from the waiver.
article Official text account_balance Process page
Expired
Citizen Poll
No votes cast
Additional Information
Print number: 117_HRES_1169
Sponsor: Rep. Smith, Adrian [R-NE-3]
Process start date: 2022-06-09
Lustra uses Artificial Intelligence. Verify details in source documents.
Summarized by: gemini-2.5-flash-preview-05-20
Source data: api.congress.gov
AI work logs for this document launch

OFFICIAL LEGAL TITLE

Requesting the President to transmit certain information to the House of Representatives relating to the proposed waiver of intellectual property commitments under the World Trade Organization Agreement on Trade- Related Aspects of Intellectual Property Rights.

FREQUENTLY ASKED QUESTIONS

What is the official ID of this bill?

The official print number for this legislation is 117_HRES_1169.

Which chamber initiated this legislation?

This legislation was initiated in the House of Representatives.

When did the legislative process begin?

The process officially started on 2022-06-09.

What are the main provisions?

Key points include:

  • The House wants to know if waiving intellectual property rights for COVID-19 vaccines will increase global supply and delivery.
  • The request also seeks to determine if such a waiver will accelerate the end of the COVID-19 pandemic.
  • There is concern about whether China would gain access to vaccine patents, even if explicitly excluded from the waiver.
What is the specific legal status?

The current status is Expired.

Where can I read the full text of this legislation?

The full official text is available at: View full text

Who is the primary sponsor?

The primary sponsor is Rep. Smith, Adrian [R-NE-3].

What is the latest detailed status?

The latest detailed status is: Referred to the Subcommittee on Trade.

Is this summary verified?

Yes. This content was analyzed by AI and verified by the Lustra Judge System on 2025-12-27.

CATEGORIES

Health Courts and Law Economy